Summary
Compugen Ltd (Compugen) is a drug discovery company that develops medicines for immuno-oncology and autoimmune diseases. The company’s immuno-oncology pipeline comprises CGEN-15001T, CGEN-15022, CGEN-15022, CGEN-15029, target candidates, immuno-modulatory target candidates and ADC target candidates. Its drug development process include target discovery, target validation and predictive discovery programs. The company also offers targets for antibody drug conjugate therapy. It offers predictive theories for integration process containing biology knowledge, genome and proteome analysis, and experimental and disease data; computational model; and novel and non-novel candidates. Compugen is headquartered in Holon, Israel.
Compugen Ltd (CGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Compugen Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Compugen Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Compugen Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Compugen Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Neviah Genomics Raises Additional Funds through Venture Financing 12
Partnerships 12
Compugen Enters into Research Agreement with Johns Hopkins University School of Medicine 12
BioLineRx Enters Into Co-Development Agreement With Compugen 13
Compugen Enters Into Co-Marketing Agreement With DiscoveRx 14
Licensing Agreements 15
Compugen Enters Into Licensing Agreement With Bayer HealthCare For Cancer Immunotherapies 15
Equity Offering 17
Compugen Completes Public Offering Of Shares For US$72.5 Million 17
Evogene Completes Public Offering Of Shares For US$84.8 Million 18
Keddem Bioscience Announces Private Placement Of Common Stock For US$15 Million 19
Compugen Announces Private Placement Of Shares For US$8 Million 20
Compugen Files Registration Statement For Public Offering Of Common Stock For US$40 Million 21
Compugen Ltd - Key Competitors 23
Key Employees 24
Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
May 09, 2017: Compugen Reports First Quarter 2017 Results 26
Feb 15, 2017: Compugen Reports Fourth Quarter and Calendar Year 2016 Results 27
Nov 07, 2016: Compugen Reports 3rd Quarter 2016 Financial Results 28
Aug 02, 2016: Compugen Reports 2nd Quarter 2016 Financial Results 29
May 10, 2016: Compugen Reports First Quarter 2016 Financial Results 30
Feb 09, 2016: Compugen Reports Fourth Quarter and Calendar 2015 Results 31
Corporate Communications 32
Mar 08, 2017: Compugen Announces Addition of Prof. Miriam Merad to Its Scientific Advisory Board 32
Product News 33
Aug 30, 2016: Compugen Discloses Development of Enhanced LINKS Platform Utilized for the Discovery of Myeloid Targets for Cancer Immunotherapy 33
Jun 22, 2016: Compugen Discloses Lead Therapeutic Candidate for CGEN-15029 Immuno-Oncology Program 34
Mar 28, 2017: Compugen Announces Lead Therapeutic Candidate COM902 for CGEN-15137/TIGIT Immuno-Oncology Program 35
Mar 02, 2017: Compugen Announces Presentations of COM701 Immuno-oncology Pipeline Product and Predictive Discovery Methodology for Novel Immune Checkpoints at AACR 36
Feb 29, 2016: Compugen Presents Results for CGEN-15029 Immuno-Oncology Therapeutic Program 37
Jan 04, 2017: Compugen's CGEN-15001 Demonstrates Restoration of Immune Tolerance in Autoimmunity 38
Clinical Trials 39
May 04, 2017: Compugen to Present COM701 Checkpoint Product Candidate for Immuno-Oncology at ASCO 39
Dec 07, 2016: Compugen Discloses its Cancer Immunotherapy Program Targeting TIGIT Immune Checkpoint 40
Nov 11, 2016: Compugen Immune Checkpoint Program Demonstrates Potential for Development of New Cancer Immunotherapy Treatments 41
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43
List of Tables
Compugen Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Compugen Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Compugen Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Compugen Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Compugen Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Neviah Genomics Raises Additional Funds through Venture Financing 12
Compugen Enters into Research Agreement with Johns Hopkins University School of Medicine 12
BioLineRx Enters Into Co-Development Agreement With Compugen 13
Compugen Enters Into Co-Marketing Agreement With DiscoveRx 14
Compugen Enters Into Licensing Agreement With Bayer HealthCare For Cancer Immunotherapies 15
Compugen Completes Public Offering Of Shares For US$72.5 Million 17
Evogene Completes Public Offering Of Shares For US$84.8 Million 18
Keddem Bioscience Announces Private Placement Of Common Stock For US$15 Million 19
Compugen Announces Private Placement Of Shares For US$8 Million 20
Compugen Files Registration Statement For Public Offering Of Common Stock For US$40 Million 21
Compugen Ltd, Key Competitors 23
Compugen Ltd, Key Employees 24
Compugen Ltd, Subsidiaries 25List of Figures
Compugen Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Compugen Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Compugen Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Compugen Ltd, Medical Devices Deals, 2011 to YTD 2017 10
